Table 1.
Correlation between mitochondrial superoxide dismutase (SOD2) expression and clinicopathological characteristics in 61 endometriosis-associated ovarian cancers
| Characteristic | Cases, n | SOD2 expression, n | P value | |
|---|---|---|---|---|
| High (n = 46) | Low (n = 15) | |||
| Age, years | ||||
| 60< | 11 | 10 | 1 | 0.2646 |
| ≤ 60 | 50 | 36 | 14 | |
| FIGO class | ||||
| Low (I, II) | 51 | 38 | 13 | 0.9999 |
| High (III, IV) | 10 | 8 | 2 | |
| Blood marker | ||||
| Positive | 48 | 37 | 11 | 0.7175 |
| Negative | 13 | 9 | 4 | |
| Histology | ||||
| Clear cell | 41 | 33 | 8 | 0.2164 |
| Endometrioid | 20 | 13 | 7 | |
| Treatment | ||||
| Complete | 53 | 41 | 12 | 0.3934 |
| Incomplete | 8 | 5 | 3 | |
Patients were stratified according to mitochondrial superoxide dismutase (SOD2) expression. SOD2 expression was not associated with age, International Federation of Gynecology and Obstetrics (FIGO) stage, blood markers, histology, or completeness of adjuvant primary treatment